financetom
NSTG
financetom
/
Healthcare
/
NSTG
All stocks News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Commodities
NanoString Technologies, Inc.NSTG
USD
- At close
USD
- Until the end
The complete list of US stocks
1D
5D
1M
1Y
5Y
MAX
Overview >
% Change
Description >

NanoString Technologies, Inc. develops, manufactures, and sells technology for scientific and clinical information in the fields of genomics and proteomics in the Americas, Europe, the Middle East, and the Asia Pacific.

The company offers nCounter Analysis System, an automated, multi-application, digital detection, and counting system.

It provides nCounter Pro and FLEX systems that include Prep Station, an automated liquid handling component that processes and prepares samples for data collection; and nCounter Digital Analyzer, which collects data from samples by taking images of the immobilized fluorescent reporters in the sample cartridge and processing the data into output files.

The company also offers nCounter SPRINT Profiler, an instrument that provides liquid handling steps and the digital analysis through use of a microfluidic cartridge; and nSolver Analysis Software, a data analysis program that enables researchers to check, normalize, and analyze their data.

In addition, it provides custom CodeSets; panels with oncology, immunology and infectious disease, and neuroscience applications.

Further, the company offers Master Kits, cartridges, ancillary reagents, tips and reagent plates to setup and process samples in instruments; and Prosigna in vitro diagnostic kits.

The company is also developing GeoMx DSP system to enable the field of spatial biology. It has collaboration with Lam Research Corporation for the development of NGS sequencing platform and related assays; and Parker Institute for Cancer Immunotherapy to develop CAR-T regimens that enhances patient outcomes for various types of cancer, as well as collaboration with Stanford Medicine, Acrobat Genomics, and Illumina Accelerator to discover new drug targets for gene editing-based therapeutics.

NanoString Technologies, Inc. was incorporated in 2003 and is headquartered in Seattle, Washington.

Latest News >
MPLX posts drop in Q2 net income
MPLX posts drop in Q2 net income
Aug 5, 2025
Overview * MPLX ( MPLX ) Q2 net income falls to $1.048 bln from $1.176 bln yr ago * Adjusted EBITDA rises to $1.690 bln, reflecting growth strategy execution Result Drivers * CRUDE OIL LOGISTICS - Higher rates and throughputs drove growth in adjusted EBITDA, partially offset by increased operating expenses * NATURAL GAS SERVICES - Segment adjusted EBITDA slightly...
Willis Lease Q2 revenue up 29.4%, beats estimates
Willis Lease Q2 revenue up 29.4%, beats estimates
Aug 5, 2025
Overview * Willis Lease Q2 revenue rises 29.4% to $195.5 mln, beating expectations * Record pre-tax income of $74.3 mln achieved in Q2 2025 * Co's portfolio utilization increased to 88.3% at quarter end Outlook * Company cites aviation market strength as a driver for future leasing demand Result Drivers * LEASE RENT REVENUE - Lease rent revenue increased by...
Google agrees $36 million fine for anti-competitive deals with Australia telcos
Google agrees $36 million fine for anti-competitive deals with Australia telcos
Aug 17, 2025
SYDNEY, Aug 18 (Reuters) - Google agreed on Monday to pay a A$55 million ($35.8 million) fine in Australia after the consumer watchdog found it had hurt competition by paying the country's two largest telcos to pre-install its search application on Android phones, excluding rival search engines. The fine extends a bumpy period for the Alphabet-owned internet giant in Australia,...
Pfizer raises annual profit forecast
Pfizer raises annual profit forecast
Aug 5, 2025
(Reuters) -U.S. drugmaker Pfizer ( PFE ) raised its full-year profit forecast on Tuesday after reporting better-than-expected results for the second quarter, boosted by strong demand for its heart disease drug, Vyndaqel, and blood thinner, Eliquis. The drugmaker now expects to earn $2.90 to $3.10 per share on an adjusted basis in 2025, compared with its previous expectations of $2.80...
Copyright 2023-2026 - www.financetom.com All Rights Reserved